---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-206382"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:21:46.819014+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports Q1 net loss $13.2M; cash runway extended to 2030 after $162M offering

## Summary
- Net loss of $13.2M in Q1 2026 vs $10.3M YoY; R&D expenses $9.9M, G&A $5.0M.
- Cash, equivalents and marketable securities $171.8M at March 31; April offering net ~$162M.
- FDA alignment on Phase 3 plan for Haduvio in IPF-related chronic cough; first Phase 3 starts Q2 2026.
- Phase 2b in refractory chronic cough starts Q2 2026; Phase 2b in non-IPF ILD cough starts H2 2026.
- European patent granted for nalbuphine ER in IPF cough, expiration 2039.

## SEC filing metadata
- accession: 0001193125-26-206382
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312526206382/0001193125-26-206382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312526206382/trvi-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-206382
- JSON: https://secwatch.observer/filing/0001193125-26-206382.json
- Plain text: https://secwatch.observer/filing/0001193125-26-206382.txt

## Source-grounded claims
- claim_id: 0e32a8fd60d21d135c6afba34e18faeef2b4c854
  claim: Trevi Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss: For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10.
  evidence_excerpt: For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10.3 million in the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000119312526206382/0001193125-26-206382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.